Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure - results of the Polish survey in the context of EULAR recommendations

about

Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure - results of the Polish survey in the context of EULAR recommendations

Item

http://www.wikidata.org/entity/Q36842389

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Rheumatoid arthritis treatment ...... ntext of EULAR recommendations

@en

type

Item

label

Rheumatoid arthritis treatment ...... ntext of EULAR recommendations

@en

prefLabel

Rheumatoid arthritis treatment ...... ntext of EULAR recommendations

@en

P1476

Rheumatoid arthritis treatment ...... ntext of EULAR recommendations

@en

P2093

Grażyna Dębowska

http://www.w3.org/2001/XMLSchema#string

Joanna Spytek

http://www.w3.org/2001/XMLSchema#string

Małgorzata Tłustochowicz

http://www.w3.org/2001/XMLSchema#string

Witold Tłustochowicz

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

P304

200-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/REUM.2015.53997

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27407248

http://www.w3.org/2001/XMLSchema#string

P932

4847287

http://www.w3.org/2001/XMLSchema#string